New Assays for Sepsis

Two new assays measure levels of adenosine deaminase-binding protein (ADBP), which has been shown to rise in urine samples prior to onset of both sepsis and acute renal failure.

The assays were developed as a new diagnostic/therapeutic regime for sepsis and acute renal failure (SARF) and both are for research use only. The assay for sepsis is called ABP-26, and the assay for acute renal failure is called Nephroscreen. They are designed to enable detection and the use of preventive therapy far earlier than current diagnostic regimes. The assays were developed by Signet Laboratories (Dedham, MA, USA).

Other new immunopathology products from Signet include P504, an antibody aiding the diagnosis of prostate cancer and neoplastic changes in prostate biopsies; and the Acuity mouse-on-mouse polymer detection system, a system for use with monoclonal and polyclonal antibodies on mouse or rate tissue. Acuity provides cost savings by enabling researchers to use less antibody, while increasing staining intensity and eliminating background.

Over the past year, Signet has launched an array of monoclonal and polyclonal antibodies and enzyme-linked immunosorbent assay (ELISA) kits for cancer, infectious disease, and neurodegenerative disease. The company has recently announced the expansion of its product line of diagnostic assays and antibodies for detecting and treating critical disease states.

"Our goal is to continue to create new reagents and diagnostics that predict emergence of disease, and develop therapies as reliable preventive weapons against disease in clinical setting,” explained Dr. Richard Gill, president and CEO of Signet Labs.




Related Links:
Signet Labs